OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel ...

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...

Leerink analyst Roanna Ruiz downgraded Lexicon (LXRX) to Market Perform from Outperform with a price target of $1, down from $2. The “modest” ...

Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...

Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced ...

Stock analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of DENTSPLY SIRONA in a ...

Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for argenx in a research report issued to clients ...

Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will par ...

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet ...

The webcast of the fireside chat will be accessible in the investor section of 89bio’s website. A replay of the webcast will be available for approximately 30 days following the conference.

Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...

today announced that members of its senior leadership team will participate in a fireside chat at the Leerink Partners Global ...